Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C

被引：0
|
作者：
Necchi, A. [1 ,2 ]
Shore, N. D. [3 ]
Gupta, S. [4 ]
Kulkarni, G. [5 ]
Dave, H. [6 ]
Kapadia, E. [6 ]
Zhao, Q. [6 ]
Kamat, A. [7 ]
机构：
[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Milan, Italy
[2] Sci Inst, Dept Med Oncol, Milan, Italy
[3] Carolina Urol Res Ctr, Dept Urol, Myrtle Beach, SC USA
[4] Cleveland Clin, Taussig Canc Ctr, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
[5] Univ Toronto, Univ Hlth Network, Dept Surg Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Merck & Co Inc, Clin Res, Rahway, NJ 07065 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Urol Oncol, Houston, TX 77030 USA
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0522
引用
收藏
页码：S748 / S748
页数：1
相关论文
共 50 条
  • [41] CORE1: PHASE 2, SINGLE ARM STUDY OF CG0070 COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)
    Li, Roger
    Steinberg, Gary
    Lamm, Donald
    Uchio, Ed M.
    Shah, Paras
    Kamat, Ashish M.
    Hnat, Nataliya
    Chisamore, Michael J.
    Grandi, Paola
    Burke, James
    [J]. JOURNAL OF UROLOGY, 2022, 207 (05): : E927 - E927
  • [42] CORE1: PHASE 2, SINGLE ARM STUDY OF CG0070 COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)
    Li, Roger
    Steinberg, Gary
    Lamm, Donald
    Uchio, Ed
    Packiam, Vignesh
    Kamat, Ashish
    Chisamore, Michael
    McAdory, John
    Grandi, Paola
    Kim, Jee-Hyun
    Burke, James
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A1005 - A1005
  • [43] Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guerin for patients with high-risk non-muscle invasive bladder cancer
    Jamil, Marcus L.
    Deebajah, Mustafa
    Sood, Akshay
    Robinson, Kathy
    Rao, Krishna
    Sana, Sherjeel
    Alanee, Shaheen
    [J]. BMJ OPEN, 2019, 9 (07):
  • [44] Punch: Preliminary results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).
    Wang, Zongren
    Zhan, Wenhao
    Huang, Bin
    Luo, Cheng
    Chen, Lingwu
    Chen, Junxing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 618 - 618
  • [45] Bacillus Calmette-Guerin (BCG) and alternatives Drug treatment of high-risk non-muscle invasive bladder cancer
    Leucht, K.
    Foller, S.
    Grimm, Marc-Oliver
    [J]. UROLOGE, 2021, 60 (11): : 1400 - 1408
  • [46] CORE1: Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
    Rixe, Olivier
    Castonguay, Vincent
    Conter, Henry
    Chalas, Eva
    Desai, Pratibha
    Squillante, Christian
    MacDonald, Lisa A.
    Conlon, Rebekah
    Bramhecha, Yogesh
    Hirsch, Heather
    Graff, Jeremy R.
    Fiset, Stephan
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [47] Emerging intravesical therapies for the management of bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward
    Chehroudi, Ali Cyrus
    Black, Peter C.
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (06): : 204 - 213
  • [48] VISUAL DETECTION OF RECURRENCES POST BACILLUS-CALMETTE-GUERIN (BCG) FOR HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): ARE WE ADHERING TO THE GUIDELINES?
    Ranasinghe, W.
    Aw, I.
    Azer, S.
    Woodford, R.
    Mohotti, J.
    Cetti, R.
    Gibson, L.
    Webb, C.
    Bolton, D.
    Sengupta, S.
    Frydenberg, M.
    Appu, S.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 42 - 42
  • [49] Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-Guerin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): KEYNOTE-676 cohort B.
    Kamat, Ashish M.
    Shariat, Shahrokh
    Steinberg, Gary D.
    Alanee, Shaheen Riadh
    Nishiyama, Hiroyuki
    Nam, Kijoeng
    Kapadia, Ekta
    Shore, Neal D.
    Hahn, Noah M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [50] Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301.
    Hayne, Dickon
    Stockler, Martin R.
    Martin, Andrew James
    McCombie, Steve P.
    Zebic, Danka Sinikovic
    Bastick, Patricia A.
    Beardsley, Emma Kate
    Frydenberg, Mark
    Green, William
    Grummet, Jeremy
    Hawks, Cynthia
    Ischia, Joseph
    Mitterdorfer, Andrew
    Patel, Manish
    Roberts, Matthew
    Sengupta, Shomik
    Srivastav, Ratnesh Kumar
    Redfern, Andrew David
    Davis, Ian D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345